Workflow
Trevena(TRVN)
icon
搜索文档
Trevena(TRVN) - 2021 Q1 - Quarterly Report
2021-05-06 19:14
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdicti ...
Trevena(TRVN) - 2020 Q4 - Earnings Call Transcript
2021-03-10 03:55
Trevena, Inc. (OTC:TRVN) Q4 2020 Earnings Conference Call March 9, 2021 8:00 AM ET Company Participants Barry Shin - Chief Financial Officer Carrie Bourdow - President & Chief Executive Officer Bob Yoder - Chief Commercial Officer Greg Hammer - Stanford University Medical Center Mark Demitrack - Chief Medical Officer Conference Call Participants Dana Flanders - Guggenheim Brandon Folkes - Cantor Fitzgerald Jason Butler - JMP Securities Chris Bialas - H.C. Wainwright Barry Shin Good morning, and welcome ever ...
Trevena (TRVN) Investor Presentation - Slideshow
2021-03-10 01:01
INNOVATING FOR PATIENTS Nasdaq TRVN I March 2021 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the "Company" or "we"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or ac ...
Trevena(TRVN) - 2020 Q4 - Annual Report
2021-03-09 20:04
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1469215 (State or Other Juri ...
Trevena (TRVN) Investor Presentation - Slideshow
2020-11-17 06:16
INNOVATING FOR PATIENTS Nasdaq TRVN I November 2020 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the "Company" or "we"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or ...
Trevena(TRVN) - 2020 Q3 - Quarterly Report
2020-11-02 20:03
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisd ...
Trevena (TRVN) Investor Presentation - Slideshow
2020-08-22 00:14
INNOVATING FOR PATIENTS Nasdaq TRVN I August 2020 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the "Company" or "we"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or a ...
Trevena(TRVN) - 2020 Q2 - Quarterly Report
2020-08-10 18:31
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36193 Trevena, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdictio ...
Trevena (TRVN) Investor Presentation - Slideshow
2020-05-19 20:08
INNOVATING FOR PATIENTS Nasdaq TRVN I May 2020 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the "Company" or "we"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achi ...
Trevena(TRVN) - 2020 Q1 - Earnings Call Transcript
2020-05-08 00:47
Trevena, Inc. (OTC:TRVN) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Robert Yoder - Senior Vice President and Chief Business Officer Carrie Bourdow - President and Chief Executive Officer Mark Demitrack - Senior Vice President and Chief Medical Officer Barry Shin - Senior Vice President and Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities Douglas Tsao - H.C. Wainwright & Co., LLC Operator Ladies and gentlemen, thank you for standing by, and ...